Home Earnings Analysis Healthcare  Summary Pfizer reported Q1 revenues of $14.5bn, with adjusted EPS down 18% and a 6.54% dividend yield. PFE faces major patent expirations on key drugs like Eliquis and Vyndaqel, pressuring future revenues despite recent M&A and pipeline efforts. Recent acquisitions, including Seagen, have yet to deliver material commercial upside, while high debt limits further M&A flexibility, although the Metsera deal is promising. With rising costs and limited near-term catalysts, PFE resembles a fixed-income play, offering a strong dividend but little share price upside. When I think of Pfizer, I can't help thinking of the Ramones lyrics about being stuck in second gear and it rarely being Pfizer's week, month, or even year. This idea was discussed in more depth with members of my private investing community, Haggerston BioHealth.…